Cytomx Therapeutics
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
151 Oyster Point Blvd Ste 400, South San...Phone Number
(650) 515-3185Website
www.cytomx.comRevenue
$35.5 MillionStock Symbol
CTMXIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
2
2
About Cytomx Therapeutics
CytomX Therapeutics is a NASDAQ-listed clinical-stage biopharmaceutical company dedicated to revolutionizing oncology treatments. The company utilizes its proprietary Probody® therapeutic platform to develop conditionally activated, masked biologic drugs. This technology is designed to localize drug activity specifically to the tumor microenvironment, thereby increasing efficacy against cancer while minimizing damage and toxicity to healthy tissues throughout the rest of the body. CytomX's robust pipeline includes Probody drug conjugates (ADCs) and T-cell engaging bispecific antibodies, targeting unmet needs in solid tumors and other cancers. The company operates on a hybrid business model, generating revenue through extensive R&D and milestone payments from major strategic partnerships with pharmaceutical leaders like Bristol Myers Squibb and Amgen.Explore more
Cytomx Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cytomx Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Cytomx Therapeutics has new funding data
Check out if Cytomx Therapeutics is spiking on competitors!
Cytomx Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Cytomx Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Cytomx Therapeutics recently announced quarterly report
Check if Cytomx Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Cytomx Therapeutics
Product Launch: Get notified when Cytomx Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined Cytomx Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Cytomx Therapeutics
Compare insights from companies similar to Cytomx Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Cytomx Therapeutics
$35.5M
51-200
Public
$341.2M
2008
YC
Yu-Waye ChuSenior Vice President, Chief Medical Officer
Company Profile Activity
Activity Insights
Cytomx Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cytomx Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cytomx Therapeutics.
Cytomx Therapeutics financials insights
Gather financial insights about Cytomx Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series A
$1.3M
2012
Series B
$41M
2015
Multiple Rounds
$182M
2018
Stock Offering
$116.9M
Cytomx Therapeutics Tech Stack
A closer look at the technologies used by Cytomx Therapeutics
See more technologies
Most Recent Scoops
Project
reported that the March 2026 Varseta-M expansion phase update showed no evidence of EpCAM-mediated toxicities, a very low incidence of hematologic toxicities, no interstitial lung disease.
Medical Research
Project
Cytomx Therapeutics has initiated a bevacizumab combination study for Varseta-M, with first data expected in the first half of 2027, as a foundational step toward advancing the drug into third-line colorectal cancer treatment with no anticipated overlapping toxicities between the two agents.
Medical Research, Pharmaceuticals
Project
presented an update from the Varseta-M expansion phase in March 2026, showing overall response rates of 20% to 32% across three dose levels (7.2, 8.6, and 10 mg/kg, with 20 patients enrolled at each) in a fourth-line or later colorectal cancer population, compared to an approximately 1% to 2% response rate for current standard of care, with a median progression-free survival of 7 months versus approximately 2 to 3 months for standard of care.
Medical Research, Clinical Operations
Project
Cytomx Therapeutics has announced plans to initiate chemotherapy combination studies for Varseta-M in the second half of the current year, with the ultimate goal of replacing irinotecan in the second-line FOLFIRI regimen given that Varseta-M employs the same topo I mechanism in a superior antibody drug conjugate format.
Medical Research, Pharmaceuticals
Project
Pharmaceuticals, Clinical Operations
Cytomx Therapeutics News & Media
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
Varsetatug masetecan (“Varseta-M”) Program:CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Alejandra Carvajal as Chief Legal Officer. In this role, Ms. Carvajal will support the Company’s strategic, operational, and pipeline initiatives.CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report second quarter financial results on Thursday, August 6, 2026, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Charles Fuchs, M.D., M.P.H., to its Board of Directors.
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Cytomx Therapeutics
Sign Up For FreeTo access detailed company insights
CytomX Therapeutics is a NASDAQ-listed clinical-stage biopharmaceutical company dedicated to revolutionizing oncology treatments. The company utilizes its proprietary Probody® therapeutic platform to develop conditionally activated, masked biologic drugs. This technology is designed to localize drug activity specifically to the tumor microenvironme... Read More
